Galapagos/€GLPG
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Galapagos
Galapagos NV, abbreviated as GLPG on stock exchanges, is a global biotechnology firm specializing in the discovery and development of small molecule medicines. The company focuses on innovating treatments primarily in the fields of immunology and oncology. Founded in 1999, Galapagos operates out of its headquarters in Belgium and extends its reach across Europe and the United States, aiming to provide transformative therapies for significant unmet medical needs.
Ticker
€GLPG
Sector
Primary listing
AEX
Industry
Biotechnology
Headquarters
Employees
558
Website
Galapagos Metrics
BasicAdvanced
€1.9B
-
-€4.31
-0.02
-
Price and volume
Market cap
€1.9B
Beta
-0.02
52-week high
€31.08
52-week low
€20.00
Average daily volume
70K
Financial strength
Current ratio
8.079
Quick ratio
7.89
Long term debt to equity
0.229
Total debt to equity
0.319
Interest coverage (TTM)
-363.88%
Profitability
EBITDA (TTM)
-298.983
Gross margin (TTM)
39.43%
Net profit margin (TTM)
-103.11%
Operating margin (TTM)
-120.26%
Effective tax rate (TTM)
0.84%
Revenue per employee (TTM)
€490,000
Management effectiveness
Return on assets (TTM)
-5.11%
Return on equity (TTM)
-10.39%
Valuation
Price to revenue (TTM)
6.787
Price to book
0.67
Price to tangible book (TTM)
0.73
Price to free cash flow (TTM)
-6.268
Free cash flow yield (TTM)
-15.96%
Free cash flow per share (TTM)
-4.522
Growth
Revenue change (TTM)
5.45%
Earnings per share change (TTM)
-200.41%
3-year revenue growth (CAGR)
-18.29%
10-year revenue growth (CAGR)
12.90%
3-year earnings per share growth (CAGR)
52.03%
10-year earnings per share growth (CAGR)
9.00%
What the Analysts think about Galapagos
Analyst ratings (Buy, Hold, Sell) for Galapagos stock.
Bulls say / Bears say
Galapagos' strategic decision to spin off its innovative medicines unit by mid-2025 aims to provide clearer business prospects for investors, potentially enhancing shareholder value. (reuters.com)
The company's collaboration with Adaptimmune to develop TCR T-cell therapy candidate uza-cel for head & neck cancer, with potential milestone payments up to $465 million, signifies a strong commitment to expanding its oncology pipeline. (newsfilecorp.com)
Galapagos' partnership with BridGene Biosciences to develop a selective oral SMARCA2 PROTAC for precision oncology underscores its focus on innovative cancer treatments, with BridGene eligible for up to $159 million in payments. (stocktitan.net)
Multiple analysts have downgraded Galapagos' stock, with StockNews.com lowering its rating to 'sell' in April 2025, reflecting concerns about the company's financial outlook. (defenseworld.net)
The planned reorganization is expected to lead to the reduction of around 300 positions in Europe, or around 40% of the group's workforce, indicating potential operational challenges. (reuters.com)
Galapagos' stock has faced significant devaluation since late 2020, following the decision not to pursue FDA approval for its experimental rheumatoid arthritis treatment, raising concerns about its product pipeline. (reuters.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jul 2025.
Galapagos Financial Performance
Revenues and expenses
Galapagos Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Galapagos stock?
Galapagos (GLPG) has a market cap of €1.9B as of July 30, 2025.
What is the P/E ratio for Galapagos stock?
The price to earnings (P/E) ratio for Galapagos (GLPG) stock is 0 as of July 30, 2025.
Does Galapagos stock pay dividends?
No, Galapagos (GLPG) stock does not pay dividends to its shareholders as of July 30, 2025.
When is the next Galapagos dividend payment date?
Galapagos (GLPG) stock does not pay dividends to its shareholders.
What is the beta indicator for Galapagos?
Galapagos (GLPG) has a beta rating of -0.02. This means that it has an inverse relation to market volatility.